Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Diehl · SciRah

Researcher profile · Semantic Scholar

V. Diehl

Share profile

V. Diehl — researcher profile on SciRah

h-index: 77
Works: 728
Citations: 31K

Most-cited papers

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
A. Engert, H. Haverkamp, C. Kobe, J. Marková +27 more
2012The Lancet567 citations
Semantic Scholar
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
H. Eich, V. Diehl, H. Görgen, T. Pabst +16 more
2010Journal of Clinical Oncology411 citations Open access
Semantic Scholar
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
P. Borchmann, H. Goergen, C. Kobe, A. Lohri +32 more
2017The Lancet341 citations
Semantic Scholar
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
B. von Tresckow, A. Plütschow, M. Fuchs, B. Klimm +14 more
2012Journal of Clinical Oncology286 citations
Semantic Scholar
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
K. Behringer, H. Mueller, H. Goergen, Indra Thielen +16 more
2013Journal of Clinical Oncology243 citations Open access
Semantic Scholar
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
M. Fuchs, H. Goergen, C. Kobe, G. Kuhnert +25 more
2019Journal of Clinical Oncology188 citations Open access
Semantic Scholar
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
N. Skoetz, S. Trelle, M. Rancea, H. Haverkamp +3 more
2013The Lancet Oncology184 citations
Semantic Scholar
PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
Sarah A. Meadows, F. Vega, A. Kashishian, D. Johnson +4 more
2012Blood168 citations
Semantic Scholar
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.
A. Josting, H. Müller, P. Borchmann, J. Baars +15 more
2010Journal of Clinical Oncology168 citations Open access
Semantic Scholar
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
K. Behringer, H. Goergen, F. Hitz, J. Zijlstra +32 more
2015The Lancet167 citations
Semantic Scholar
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
P. Borchmann, A. Plütschow, C. Kobe, R. Greil +32 more
2021The Lancet Oncology137 citations Open access
Semantic Scholar
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
D. Eichenauer, Indra Thielen, H. Haverkamp, J. Franklin +11 more
2014Blood134 citations Open access
Semantic Scholar
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
S. Sasse, P. Bröckelmann, H. Goergen, A. Plütschow +8 more
2017Journal of Clinical Oncology128 citations
Semantic Scholar
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
B. Böll, H. Goergen, K. Behringer, P. Bröckelmann +11 more
2016Blood113 citations
Semantic Scholar
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.
S. Kreissl, H. Mueller, H. Goergen, Axel Mayer +12 more
2016The Lancet Oncology106 citations
Semantic Scholar
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
D. Eichenauer, A. Plütschow, S. Kreissl, M. Sökler +13 more
2017The Lancet Oncology102 citations
Semantic Scholar
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
B. Böll, H. Görgen, M. Fuchs, A. Pluetschow +13 more
2013Journal of Clinical Oncology99 citations
Semantic Scholar
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration.
K. Behringer, H. Goergen, H. Müller, Indra Thielen +13 more
2016Journal of Clinical Oncology93 citations
Semantic Scholar
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
D. Eichenauer, A. Plütschow, M. Fuchs, B. von Tresckow +6 more
2015Journal of Clinical Oncology92 citations
Semantic Scholar
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
P. Borchmann, H. Haverkamp, A. Lohri, U. Mey +18 more
2017The Lancet Oncology80 citations
Semantic Scholar
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
Diana Wongso, M. Fuchs, A. Plütschow, B. Klimm +10 more
2013Journal of Clinical Oncology67 citations Open access
Semantic Scholar
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
D. Eichenauer, A. Plütschow, M. Fuchs, S. Sasse +6 more
2020Journal of Clinical Oncology62 citations
Semantic Scholar
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.
B. Böll, H. Goergen, Nils Arndt, J. Meissner +12 more
2013Journal of Clinical Oncology62 citations Open access
Semantic Scholar
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
A. Engert, A. Josting, H. Haverkamp, M. Villalobos +13 more
2010Journal of Clinical Oncology60 citations Open access
Semantic Scholar
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
C. Kobe, G. Kuhnert, D. Kahraman, H. Haverkamp +15 more
2014Journal of Clinical Oncology58 citations
Semantic Scholar
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
T. Halbsguth, L. Nogova, H. Mueller, M. Sieniawski +7 more
2010Blood55 citations Open access
Semantic Scholar
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
S. Kreissl, H. Goergen, Ina Buehnen, C. Kobe +30 more
2021The Lancet Haematology49 citations Open access
Semantic Scholar
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
A. Hay, B. Klimm, B.-E. Chen, H. Goergen +16 more
2013Annals of Oncology49 citations Open access
Semantic Scholar
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
B. von Tresckow, S. Kreissl, H. Goergen, P. Bröckelmann +11 more
2018The Lancet Haematology48 citations Open access
Semantic Scholar
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group.
S. Kreissl, H. Müller, H. Goergen, J. Meissner +14 more
2020Journal of Clinical Oncology43 citations
Semantic Scholar
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
D. Eichenauer, A. Plütschow, L. Schröder, M. Fuchs +5 more
2018Blood40 citations Open access
Semantic Scholar
Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study
P. Borchmann, D. Eichenauer, A. Pluetschow, H. Haverkamp +11 more
201339 citations
Semantic Scholar
Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
B. Klimm, J. Franklin, H. Stein, D. Eichenauer +5 more
2011Journal of Clinical Oncology39 citations Open access
Semantic Scholar
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma
A. Engert, H. Goergen, J. Marková, T. Pabst +15 more
2017HemaSphere36 citations Open access
Semantic Scholar
Current status of prognostication in classical Hodgkin lymphoma
G. Venkataraman, M. K. Mirza, D. Eichenauer, V. Diehl
2014British Journal of Haematology32 citations
Semantic Scholar
ABVD versus BEACOPP for Hodgkin's lymphoma.
P. Borchmann, V. Diehl, A. Engert
2011New England Journal of Medicine26 citations
Semantic Scholar
The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma
T. Halbsguth, B. Böll, P. Borchmann, V. Diehl
2011Current Hematologic Malignancy Reports22 citations
Semantic Scholar
BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL
P. Borchmann, A. Moccia, R. Greil, G. Schneider +30 more
2023Hematological Oncology21 citations
Semantic Scholar
Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial
A. Engert, C. Kobe, J. Marková, H. Haverkamp +7 more
201021 citations
Semantic Scholar
Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial
A. Engert, P. Borchmann, A. Pluetschow, B. von Tresckow +13 more
201021 citations
Semantic Scholar
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
S. Gillessen, A. Plütschow, M. Fuchs, J. Marková +10 more
2021The Lancet Haematology19 citations Open access
Semantic Scholar
Hematology: Are macrophages the bad guys in Hodgkin lymphoma?
V. Diehl
2010Nature Reviews Clinical Oncology19 citations
Semantic Scholar
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group
M. Fuchs, H. Goergen, C. Kobe, H. Eich +12 more
2018Blood18 citations
Semantic Scholar
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
P. Borchmann, D. Eichenauer, A. Pluetschow, H. Haverkamp +11 more
2016Clinical advances in hematology & oncology : H&O18 citations
Semantic Scholar
Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
H. Haverkamp, B. Böll, D. Eichenauer, S. Sasse +5 more
2015Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma.
N. Schoof, J. Franklin, R. Fürst, T. Zander +7 more
2013The Oncologist16 citations Open access
Semantic Scholar
Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.
P. Borchmann, H. Haverkamp, A. Lohri, S. Kreissl +13 more
201415 citations
Semantic Scholar
CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma
Sarah A. Meadows, A. Kashishian, D. Johnson, V. Diehl +1 more
201015 citations
Semantic Scholar
Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives
D. Eichenauer, B. Böll, V. Diehl
2014Expert Opinion on Pharmacotherapy11 citations
Semantic Scholar
Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone
A. Hay, B. Klimm, Bing-Shu E. Chen, H. Goergen +16 more
201211 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Engert×44
Invite
A. Engert — researcher profile on SciRah
P. Borchmann×43
Invite
P. Borchmann — researcher profile on SciRah
M. Fuchs×36
Invite
M. Fuchs — researcher profile on SciRah
H. Eich×19
Invite
H. Eich — researcher profile on SciRah

×19

Invite

D. Eichenauer — researcher profile on SciRah

Invite

R. Greil — researcher profile on SciRah

J. Meissner×17

Invite

J. Meissner — researcher profile on SciRah

B. von Tresckow×17

Invite

B. von Tresckow — researcher profile on SciRah

Invite

H. Goergen — researcher profile on SciRah

J. Marková×15

Invite

J. Marková — researcher profile on SciRah

M. Dietlein×15

Invite

M. Dietlein — researcher profile on SciRah

Invite

C. Kobe — researcher profile on SciRah